Please login to the form below

Not currently logged in
Email:
Password:

antitrust

This page shows the latest antitrust news and features for those working in and with pharma, biotech and healthcare.

COVID-19 delays Pfizer, Mylan’s generics merger and spin-out

COVID-19 delays Pfizer, Mylan’s generics merger and spin-out

The Federal Trade Commission (FTC) and Department of Justice (DoJ) said this week that they were implementing an expedited antitrust procedure to make it easier for companies to work together on ... At the same time, it has warned that some antitrust

Latest news

More from news
Approximately 6 fully matching, plus 99 partially matching documents found.

Latest Intelligence

  • COVID-19 hits supply chains COVID-19 hits supply chains

    With government support, US supply-chain ecosystems can be rebuilt, but only if lawmakers aggressively enforce antitrust laws and control private equity exploitation, he added.

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    The deal was announced in June 2019 and took months to go through the antitrust regulatory process, but according to AbbVie – which agreed a massive $30bn bond issue to help finance ... of wrangling with the antitrust authorities.

  • Risky business for pharma Risky business for pharma

    to consider, including but not limited to bribery and corruption, money laundering, competition and antitrust, cybersecurity, data privacy and regulation and compliance. ... Villareal also cited “[c] ompetition and antitrust issues. as a global risk

  • Deal Watch October 2015 Deal Watch October 2015

    This deal will combine the second and third largest drug store operators in the US and as a result it will no doubt be scrutinised by the US antitrust authorities. ... Echoing some of the hefty termination provisions we saw last year in big pharma deals,

  • Pharma deals in July 2015 Pharma deals in July 2015

    However, Teva's deal with Allergan is not over yet. It is subject to review by antitrust regulators of the combined generics portfolio.

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest from PMHub

  • Blended Intelligence Blended Intelligence

    Data is the most valued commodity of the modern world. The fast-moving industry that has grown up around it is in the spotlight of antitrust regulators, poised to step in

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

Improve clinical trials through patient journey mapping
Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...
InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...

Infographics